JP2013516442A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013516442A5 JP2013516442A5 JP2012547515A JP2012547515A JP2013516442A5 JP 2013516442 A5 JP2013516442 A5 JP 2013516442A5 JP 2012547515 A JP2012547515 A JP 2012547515A JP 2012547515 A JP2012547515 A JP 2012547515A JP 2013516442 A5 JP2013516442 A5 JP 2013516442A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- patient
- compound
- compound selected
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 20
- 239000003795 chemical substances by application Substances 0.000 claims 16
- 230000001225 therapeutic effect Effects 0.000 claims 9
- 210000000577 adipose tissue Anatomy 0.000 claims 7
- 230000037396 body weight Effects 0.000 claims 4
- 208000008589 Obesity Diseases 0.000 claims 3
- 230000007423 decrease Effects 0.000 claims 3
- 239000003607 modifier Substances 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- -1 S-17092 Chemical compound 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 claims 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims 1
- YPELFRMCRYSPKZ-UHFFFAOYSA-N 4-amino-5-chloro-2-ethoxy-N-({4-[(4-fluorophenyl)methyl]morpholin-2-yl}methyl)benzamide Chemical compound CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC1OCCN(CC=2C=CC(F)=CC=2)C1 YPELFRMCRYSPKZ-UHFFFAOYSA-N 0.000 claims 1
- MJCKISCWHDATBN-UHFFFAOYSA-N 4-amino-5-chloro-n-[(1-ethyl-4,5-dihydroimidazol-2-yl)methyl]-2-methoxybenzamide Chemical compound CCN1CCN=C1CNC(=O)C1=CC(Cl)=C(N)C=C1OC MJCKISCWHDATBN-UHFFFAOYSA-N 0.000 claims 1
- FEROPKNOYKURCJ-UHFFFAOYSA-N 4-amino-N-(1-azabicyclo[2.2.2]octan-3-yl)-5-chloro-2-methoxybenzamide Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)NC1C(CC2)CCN2C1 FEROPKNOYKURCJ-UHFFFAOYSA-N 0.000 claims 1
- 102100040385 5-hydroxytryptamine receptor 4 Human genes 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 claims 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 claims 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 1
- 101000964065 Homo sapiens 5-hydroxytryptamine receptor 4 Proteins 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 229960003005 axitinib Drugs 0.000 claims 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims 1
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 claims 1
- 229960005132 cisapride Drugs 0.000 claims 1
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 claims 1
- 229960002448 dasatinib Drugs 0.000 claims 1
- 229960001433 erlotinib Drugs 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 claims 1
- 229960005101 febuxostat Drugs 0.000 claims 1
- 229960001419 fenoprofen Drugs 0.000 claims 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 1
- 229960002714 fluticasone Drugs 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 229950002371 lintopride Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000001022 morbid obesity Diseases 0.000 claims 1
- 229960004085 mosapride Drugs 0.000 claims 1
- 229960000639 pazopanib Drugs 0.000 claims 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- ZPMNHBXQOOVQJL-UHFFFAOYSA-N prucalopride Chemical compound C1CN(CCCOC)CCC1NC(=O)C1=CC(Cl)=C(N)C2=C1OCC2 ZPMNHBXQOOVQJL-UHFFFAOYSA-N 0.000 claims 1
- 229960003863 prucalopride Drugs 0.000 claims 1
- GZSKEXSLDPEFPT-IINYFYTJSA-N renzapride Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)N[C@H]1[C@H](C2)CCC[N@]2CC1 GZSKEXSLDPEFPT-IINYFYTJSA-N 0.000 claims 1
- 229950003039 renzapride Drugs 0.000 claims 1
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 claims 1
- 229950005741 rolipram Drugs 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
- QWCJHSGMANYXCW-UHFFFAOYSA-N sulfaphenazole Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=NN1C1=CC=CC=C1 QWCJHSGMANYXCW-UHFFFAOYSA-N 0.000 claims 1
- 229960004818 sulfaphenazole Drugs 0.000 claims 1
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 claims 1
- 229950007866 tanespimycin Drugs 0.000 claims 1
- IKBKZGMPCYNSLU-RGVLZGJSSA-N tegaserod Chemical compound C1=C(OC)C=C2C(/C=N/NC(=N)NCCCCC)=CNC2=C1 IKBKZGMPCYNSLU-RGVLZGJSSA-N 0.000 claims 1
- 229960002876 tegaserod Drugs 0.000 claims 1
- UIVFDCIXTSJXBB-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C[C]2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CN=C21 UIVFDCIXTSJXBB-ITGUQSILSA-N 0.000 claims 1
- 229960003688 tropisetron Drugs 0.000 claims 1
- 229960000241 vandetanib Drugs 0.000 claims 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims 1
- 229960001722 verapamil Drugs 0.000 claims 1
- 229950004681 zacopride Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10150270.6 | 2010-01-07 | ||
| EP10150270 | 2010-01-07 | ||
| PCT/EP2011/050186 WO2011083150A2 (en) | 2010-01-07 | 2011-01-07 | Obesity small molecules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013516442A JP2013516442A (ja) | 2013-05-13 |
| JP2013516442A5 true JP2013516442A5 (enExample) | 2014-02-06 |
Family
ID=43533338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012547515A Pending JP2013516442A (ja) | 2010-01-07 | 2011-01-07 | 肥満症に用いる小分子 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20130030007A1 (enExample) |
| EP (2) | EP2521594A2 (enExample) |
| JP (1) | JP2013516442A (enExample) |
| CA (1) | CA2786777A1 (enExample) |
| WO (1) | WO2011083150A2 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2675275B1 (en) * | 2011-02-14 | 2017-12-20 | The Regents Of The University Of Michigan | Compositions and methods for the treatment of obesity and related disorders |
| BR112014029301A2 (pt) * | 2012-05-25 | 2017-07-25 | Berg Llc | métodos de tratamento de síndrome metabólica através de modulação da proteína choque térmico (hsp) 90-beta |
| ES2727898T3 (es) | 2013-05-02 | 2019-10-21 | Univ Michigan Regents | Amlexanox deuterado con estabilidad metabólica mejorada |
| US20190269675A1 (en) | 2014-01-28 | 2019-09-05 | Buck Institute for Research and Aging | Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents |
| IL311537A (en) | 2014-01-28 | 2024-05-01 | Mayo Found Medical Education & Res | Methods and preparations for killing aging cells and for the treatment of diseases and disorders related to aging |
| US20170216286A1 (en) * | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
| US10023864B2 (en) | 2014-06-06 | 2018-07-17 | Berg Llc | Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta |
| EP4578865A3 (en) | 2014-08-12 | 2025-07-30 | Monash University | Lymph directing prodrugs |
| IL234962A0 (en) * | 2014-10-02 | 2015-01-29 | Yeda Res & Dev | Use of substances to treat fat-related diseases |
| US20190316204A1 (en) * | 2015-07-24 | 2019-10-17 | Korea University Research And Business Foundation | Biomarker for determining aging, determining obesity, and diagnosing cancer and diagnosing kit using same |
| CN108137482B (zh) | 2015-09-08 | 2024-03-15 | 莫纳什大学 | 定向淋巴的前药 |
| CN105287552B (zh) * | 2015-10-27 | 2018-03-20 | 中国科学院广州生物医药与健康研究院 | 阿西替尼的应用 |
| US10214536B2 (en) | 2016-01-29 | 2019-02-26 | The Regents Of The University Of Michigan | Amlexanox analogs |
| WO2017197303A1 (en) * | 2016-05-13 | 2017-11-16 | University Of North Carolina At Greensboro | Methods and compositions for the inhibition of quorum sensing in bacterial infections |
| MX392555B (es) * | 2016-09-07 | 2025-03-24 | Univ Temple | Composiciones y métodos para el tratamiento de resistencia a la insulina. |
| WO2018128485A1 (ko) * | 2017-01-05 | 2018-07-12 | 한국생명공학연구원 | 항-코티닌 키메릭 항원 수용체를 발현하는 자연살해 세포 |
| EP4306524A3 (en) | 2017-08-29 | 2024-09-11 | PureTech LYT, Inc. | Lymphatic system-directing lipid prodrugs |
| US11883497B2 (en) | 2017-08-29 | 2024-01-30 | Puretech Lyt, Inc. | Lymphatic system-directing lipid prodrugs |
| JP7249397B2 (ja) * | 2017-12-27 | 2023-03-30 | 日本化薬株式会社 | ダサチニブを有効成分とする医薬組成物 |
| CN109464443B (zh) * | 2018-10-10 | 2021-08-17 | 中国科学院广州生物医药与健康研究院 | Linifanib的新应用 |
| WO2020188496A1 (en) * | 2019-03-18 | 2020-09-24 | Moshe Rogosnitzky | Stable liquid naltrexone compositions |
| US20220339168A1 (en) * | 2019-09-19 | 2022-10-27 | Monash University | Methods and compounds for treatment of metabolic disease |
| WO2021101814A1 (en) * | 2019-11-19 | 2021-05-27 | The George Washington University | Intranasal leptin prevents opioid-induced respiratory depression in obesity |
| KR102376806B1 (ko) * | 2020-03-05 | 2022-03-21 | 주식회사 메타이뮨텍 | 오에노테인 b 유사체를 유효성분으로 포함하는 체중 감량용 조성물 |
| TW202206062A (zh) | 2020-04-24 | 2022-02-16 | 美國坦普大學 高等教育聯邦系統 | 治療非酒精性脂肪肝炎的方法 |
| JP2023159469A (ja) * | 2020-08-24 | 2023-11-01 | 国立大学法人 東京大学 | 肥満症を予防又は治療するための医薬組成物 |
| CN115624980B (zh) * | 2022-12-26 | 2023-03-10 | 四川大学 | 一种金属硒基生物催化材料及其制备方法和用途 |
| CN116549435B (zh) * | 2023-04-28 | 2024-04-09 | 中山大学附属第三医院 | 一种内质网应激抑制剂及其应用 |
| WO2025081219A1 (en) * | 2023-10-19 | 2025-04-24 | St Vincent's Institute Of Medical Research | Methods of treating conditions with sik3 inhibitors |
| CN119842713B (zh) * | 2025-02-17 | 2025-11-28 | 江苏省家禽科学研究所 | 一种靶向抑制鸡PLCB2基因表达的siRNA及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU86099A1 (fr) * | 1985-09-30 | 1987-04-02 | Pharlyse | Formes galeniques a liberation prolongee du verapamil,leur fabrication et medicaments les contenant |
| FR2625678B1 (fr) * | 1988-01-13 | 1991-06-07 | Delalande Sa | Agents anorexigenes a base de n-(quinuclidin-3-yl)-benzamides ou thiobenzamides |
| FR2681864B1 (fr) * | 1991-09-27 | 1995-03-31 | Adir | Nouveaux derives bicycliques azotes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| ES2384160T3 (es) | 1999-01-13 | 2012-07-02 | Bayer Healthcare Llc | Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38 |
| EP1140840B1 (en) | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| EP1119368A2 (en) | 1999-03-03 | 2001-08-01 | Biogen, Inc. | Methods of modulating lipid metabolism and storage |
| WO2002090504A2 (en) * | 2001-05-03 | 2002-11-14 | Curagen Corporation | Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use |
| EP1492525A2 (en) * | 2001-08-16 | 2005-01-05 | Probiodrug AG | Use of inhibitors of proline endopeptidase to modulate inositol (1,4,5) triphosphate concentration dependent on intracellular signal cascades |
| KR20030083348A (ko) * | 2002-04-22 | 2003-10-30 | 주식회사 엠디바이오알파 | 지방세포 분화 저해 활성을 가지는 프로토베르베린알칼로이드 화합물인 베르베린을 유효성분으로 함유하는비만예방 및 치료 |
| CN1481796A (zh) * | 2003-06-13 | 2004-03-17 | 吴开敏 | 治疗肥胖症的药物 |
| US20050090554A1 (en) * | 2003-09-12 | 2005-04-28 | John Devane | Treatment of gastroparesis and nonulcer dyspepsia with GABAB agonists |
| WO2005115446A2 (en) * | 2004-05-21 | 2005-12-08 | Yale University | Detection and use of prolylcarboxypeptidase |
| US8703769B2 (en) * | 2005-07-15 | 2014-04-22 | The University Of North Carolina At Chapel Hill | Use of EGFR inhibitors to prevent or treat obesity |
-
2011
- 2011-01-07 US US13/520,961 patent/US20130030007A1/en not_active Abandoned
- 2011-01-07 JP JP2012547515A patent/JP2013516442A/ja active Pending
- 2011-01-07 CA CA2786777A patent/CA2786777A1/en not_active Abandoned
- 2011-01-07 EP EP11700051A patent/EP2521594A2/en not_active Withdrawn
- 2011-01-07 EP EP13156136.7A patent/EP2633884A1/en not_active Withdrawn
- 2011-01-07 WO PCT/EP2011/050186 patent/WO2011083150A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013516442A5 (enExample) | ||
| JP2011522816A5 (enExample) | ||
| JP2015505564A5 (enExample) | ||
| JP2015515475A5 (enExample) | ||
| JP2010522242A5 (enExample) | ||
| JP2013542246A5 (enExample) | ||
| JP2016518387A5 (enExample) | ||
| JP2012520866A5 (enExample) | ||
| JP2014530874A5 (enExample) | ||
| RU2013148721A (ru) | Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения | |
| JP2016539156A5 (enExample) | ||
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| JP2014521735A5 (enExample) | ||
| NZ611628A (en) | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients | |
| JP2010518122A5 (enExample) | ||
| JP2014532647A5 (enExample) | ||
| RU2013137645A (ru) | Аналоги цистамина, применяемые для лечения болезни паркинсона | |
| JP2009533356A5 (enExample) | ||
| JP2014505107A5 (enExample) | ||
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| JP2014508758A5 (enExample) | ||
| WO2011041632A3 (en) | Combination therapies for the treatment of obesity | |
| JP2012531402A5 (enExample) | ||
| WO2010151565A3 (en) | Combination therapies for the treatment of obesity | |
| WO2010151503A3 (en) | Combination therapies for the treatment of obesity |